SCHEMBL1765036

SCHEMBL1765036

CCOC(=O)C(=O)C=C(O)c1ccc(F)c(Cl)c1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PTPN1 P18031 1/20 0.38
TSHR P16473 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CASP3 P42574 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
EGFR P00533 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12596944 0.99 MAPT (0.43) MAPTALDH1A1KDM4ELMNASMN1; SMN2
SCHEMBL1765078 0.88 MAPT (0.46) MAPTALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL4003542 0.88 MAPT (0.46) MAPTALDH1A1KDM4ESMN1; SMN2PTPN1
SCHEMBL4003545 0.88 MAPT (0.46) MAPTALDH1A1KDM4ESMN1; SMN2PTPN1
SCHEMBL12596961 0.87 ALDH1A1 (0.47) MAPTALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL13980028 0.87 MAPT (0.47) MAPTALDH1A1KDM4ESMN1; SMN2PTPN1
SCHEMBL30051010 0.87 ALDH1A1 (0.47) MAPTALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL1764891 0.85 MAPT (0.43) MAPTALDH1A1KDM4ELMNAPTPN1
SCHEMBL17163920 0.84 ALDH1A1 (0.53) MAPTALDH1A1KDM4ESMN1; SMN2TDP1
Lithium Ion SCHEMBL1765035 0.84 EGFR (0.38) MAPTALDH1A1LMNASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
EP-2254885-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AiCuris GmbH & Co. KG (DE) 2010-12-01 EP disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO MAPT 2876/4885ALDH1A1 898/4885KDM4E 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.